• Science
  • Pipeline
  • News
  • About
  • Careers
  • Contact
Seattle biotech startup Lumen Bioscience raises $11.2M to develop drugs using algae

Seattle biotech startup Lumen Bioscience raises $11.2M to develop drugs using algae

by admin | Aug 3, 2020 | Press Release

The financing allows Lumen Bioscience to continue developing technology that uses the algae spirulina to make biologics. Read More
Fred Hutch and Adaptive Biotechnologies vets raise $13M for biotech startup

Fred Hutch and Adaptive Biotechnologies vets raise $13M for biotech startup

by admin | Aug 3, 2020 | Press Release

Lumen is chasing the $1.5 billion market for natural colorants with technology that uses Spirulina.
Lumen Bioscience Announces Issuance of US Patent for Genetic Modification of Spirulina

Lumen Bioscience Announces Issuance of US Patent for Genetic Modification of Spirulina

by admin | Jul 23, 2020 | Press Release

Seattle, WA—November 26, 2018—Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, announced today that the US Patent and Trademark Office has issued Patent no. 10,131,870, entitled “Targeted...
Dr. Craig Behnke Joins Lumen Bioscience as SVP, Production and Development

Dr. Craig Behnke Joins Lumen Bioscience as SVP, Production and Development

by admin | Jul 23, 2020 | Press Release

Seattle, WA—July 9, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that Dr. Craig Behnke has joined its executive team as Senior Vice President, Production and Development. Dr. Behnke will assume...
Lumen Wins Triple Funding Boost to Advance Development of Low-Cost Therapeutics for Newborns and Infants in Developing Countries

Lumen Wins Triple Funding Boost to Advance Development of Low-Cost Therapeutics for Newborns and Infants in Developing Countries

by admin | Jul 23, 2020 | Press Release

Seattle, WA—June 13, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that the Bill & Melinda Gates Foundation has tripled its funding commitment for Lumen’s ultra-low-cost antibody therapeutics...
NIH Awards Grant to Lumen Bioscience for Cost-Effective Oral Malaria Vaccine

NIH Awards Grant to Lumen Bioscience for Cost-Effective Oral Malaria Vaccine

by admin | Jul 8, 2020 | Press Release

Seattle, WA—May 21, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that National Institutes of Health (NIH) will fund continued development of its ultra-low-cost, recombinant oral malaria vaccine. This...
« Older Entries
Next Entries »

Recent Post

  • Cognition Live Article on RePreve Trial
  • LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
  • Preventive antimicrobials: A promising solution to antibiotic resistance
  • Image Credit: © bukhta79 | stock.adobe.comPreventive Biologics May Aid the Antibiotic Resistance Crisis
  • Q&A: Biologic drugs are reinvented to treat infectious diseases

Follow on

  • Follow
  • Follow
  • Follow

  • Science
  • Pipeline
  • News
  • About

  • Careers
  • Contact
  • Privacy Policy
  • PO Terms

  • Expanded Access Policy
  • FCOI
  • Services
  • iLumenate Newsletter

©2024 Lumen Bioscience, Inc.